Twenty‐five years of Respirology: Advances in respiratory infections and tuberculosis

医学 降钙素原 内科学 肺炎 肺结核 重症监护医学 败血症 病理
作者
Cynthia Bin Eng Chee,David S.C. Hui
出处
期刊:Respirology [Wiley]
卷期号:25 (1): 32-34
标识
DOI:10.1111/resp.13737
摘要

Acute respiratory infections such as influenza and community-acquired pneumonia (CAP) are leading causes of hospitalization with significant morbidity and mortality. Tuberculosis (TB) is one of the top 10 global causes of death and the leading cause from a single infectious agent. As part of Respirology's 25-year celebration, we present an opinion on advances in diagnosis and treatment of these common respiratory infections. Influenza and CAP continue to be important. The availability of pneumococcal vaccines and multiplex polymerase chain reactions (PCR) has led to a decreasing incidence of pneumococcal pneumonia and detection of more viral aetiologies in CAP. In recent years, rapid and automated molecular tests based on nucleic acid amplification have become available, with high sensitivity for detection of influenza A, influenza B and respiratory syncytial virus (RSV).1 Fibroblast growth factor 21 was shown in a secondary analysis of two randomized controlled trials (RCT) to be an effective biomarker in discriminating patients with moderate to severe CAP, predicting longer hospital length of stay (LOS) and 30-day mortality (adjusted odds ratio (OR): 1.61 (95% CI: 1.21–2.14; P = 0.001)) in comparisons to procalcitonin and C-reactive protein.2 Implementation of rapid diagnostics and biomarkers in healthcare settings may facilitate management of acute respiratory infections and decision-making on appropriate use of antiviral or antibiotic therapy, hospital LOS and prevention of nosocomial transmission with infection control measures. Cardiovascular events, such as atrial fibrillation, acute myocardial infarction (AMI), ischaemic stroke and deep venous thrombosis, complicate the course of approximately one-third of patients hospitalized for CAP. These events are associated with a fivefold increase in CAP-associated 30-day mortality.3 A self-controlled case series in Canada has shown a significant association between respiratory infections (especially influenza) and AMI. Incidence ratios for AMI within 1 week after detection of influenza B, influenza A, RSV and other viruses were 10.11 (95% CI: 4.37–23.38), 5.17 (95% CI: 3.02–8.84), 3.51 (95% CI: 1.11–11.12) and 2.77 (95% CI: 1.23–6.24), respectively.4 Studies of strategies to reduce these cardiovascular complications are of interest. Oseltamivir is currently the sole influenza antiviral on the World Health Organization (WHO) Essential Medicines list. Intravenous zanamivir has been recommended in the European Union for treating complicated and potentially life-threatening influenza caused by either the influenza A or B virus in adults and children from 6 months of age if the virus is resistant to other antiviral treatments, or inhaled zanamivir is not suitable. A meta-analysis of data from 18 309 patients in 70 clinical centres has shown that initiation of a neuraminidase inhibitor (NAI) treatment on admission, regardless of time since illness onset, is associated with a 19% reduction in LOS (incidence rate ratio: 0.81; 95% CI: 0.78–0.85) versus no or later initiation of treatment among patients hospitalized with non-fatal 2009 influenza A(H1N1).5 Baloxavir is an inhibitor of polymerase acidic protein endonuclease enzyme, with strong antiviral activity against diverse influenza A and B viruses. It has broad potency against various clinically relevant subtypes of influenza A viruses (H1N2, H5N1, H5N2, H5N6, H7N9 and H9N2). In a phase III study comparing a single dose of baloxavir 40–80 mg versus placebo or oseltamivir 75 mg twice daily (bd) in otherwise healthy influenza patients with uncomplicated influenza, baloxavir significantly reduced time to alleviation of symptoms by >24 h versus placebo and was comparable to oseltamivir. In addition, baloxavir significantly reduced viral titres versus placebo or oseltamivir from 1 day post dose.6 In another phase III study of high-risk patients with influenza comparing a single dose of baloxavir 40–80 mg versus placebo or oseltamivir 75 mg bd, baloxavir is superior to placebo in shortening the time to improvement of influenza symptoms with fewer influenza-related complications. Baloxavir is superior to placebo and oseltamivir in shortening the duration of symptoms and reducing viral titres in influenza B infection. However, emergence of A/H3N2 viral mutants with polymerase/I38X substitutions in up to 10% of adolescents and adults and 23.4% of young children is of concern.7 Clinical trials comparing the adjunctive role of baloxavir in two to three doses in addition to oseltamivir against oseltamivir and placebo are in progress. Systemic corticosteroids are frequently used for the treatment of acute respiratory distress syndrome. In comparison to controls who did not receive systemic corticosteroids, high-dose systemic corticosteroids (defined as >150 mg/day methylprednisolone equivalent) was associated with increased risks of 30-day mortality (38.5% vs 7.7%, P = 0.021) and 60-day mortality (50% vs 15.4%, P = 0.022) and longer viral shedding (15 vs 13 days, P = 0.039) among patients with influenza A(H7N9) viral pneumonia. There was no difference between low dose (25–150 mg/day methylprednisolone) and controls.8 A bundled intervention including adjunctive systemic corticosteroids in the form of prednisolone acetate 50 mg/day for 7 days for patients with CAP demonstrated no evidence of effectiveness (with regard to hospital LOS, mortality and readmission) and resulted in a higher incidence of gastrointestinal bleeding in comparison with controls who did not receive systemic corticosteroids (9 (2.2%) vs 3 (0.7%)).9 The updated guideline of the American Thoracic Society and Infectious Diseases Society of America has recommended not to prescribe systemic corticosteroids routinely for CAP except for those with refractory septic shock.10 Personal protective equipment is important for healthcare workers treating patients with acute respiratory infections. In a cluster randomized real-world effectiveness study among outpatient healthcare workers from 2011 to 2015, N95 respirators versus medical masks resulted in no significant difference between the two types of masks in the incidence of laboratory-confirmed influenza (8.2% vs 7.2% healthcare personnel-seasons, respectively) (difference: 1.0% (95% CI: −0.5% to 2.5%); P = 0.18) (adjusted OR: 1.18 (95% CI: 0.95 to 1.45)).11 The declaration of TB as a global public health emergency by the WHO in 1993 proved the catalyst for governments, donor agencies and the private sector to prioritize funding for the research and development of TB diagnostics, drugs and vaccines. Development of rapid molecular-based tests to detect resistance-conferring mutations in the Mycobacterium tuberculosis (MTB) genome has been a key advance. The Xpert MTB/rifampicin (RIF) (Cepheid, Sunnyvale, CA, USA), a near point-of-care test endorsed by the WHO in 2010, has shortened the time to detection of MTB and rifampicin resistance (as a surrogate for multidrug-resistant (MDR) TB) from weeks/months to less than 2 h. It has recently been replaced by a more sensitive version, the Xpert MTB/RIF Ultra. A new cartridge, run on GeneXpert software, which detects resistance to isoniazid, fluoroquinolones and second-line injectables will be available soon. Whole-genome sequencing (WGS) is expected to expand the range of drugs for which resistance can be tested without reliance on the slower phenotypic method. Using WGS, a high degree of correlation of genotypic predictions of susceptibility of MTB to first-line drugs with their phenotypic susceptibility has been shown. Public health laboratories in England, the Netherlands and New York State have replaced phenotypic first-line drug susceptibility testing with WGS to guide clinical practice.12 Since rifampicin was approved in 1968, no new drug or drug class has been approved for TB until 2012, when bedaquiline attained accelerated US Food and Drug Administration (FDA) approval for MDR-TB treatment. In 2019, pretomanid became the third TB drug in 50 years to be FDA-approved for its use in combination with bedaquiline and linezolid for the treatment of extensively drug-resistant, treatment-intolerant or non-responsive pulmonary MDR-TB. In 2019, the first RCT on MDR-TB treatment showed non-inferiority of the shorter WHO 9–11 month (‘Bangladesh’) regimen compared to the WHO 20-month regimen in eligible patients.13 An individual patient data meta-analysis showed the treatment outcome and mortality benefit of bedaquiline, later-generation fluoroquinolones and linezolid in the longer MDR-TB treatment regimen, providing the evidence base which shaped key changes to the 2019 WHO guidelines on MDR-TB treatment.14 An injection-free MDR-TB treatment regimen is now recommended, and the second-line drugs have been re-grouped such that levofloxacin/moxifloxacin, bedaquiline and linezolid are designated high-priority drugs to be included in the longer WHO MDR-TB treatment regimen.15 Research to identify biomarkers for incipient TB and to develop tests with higher positive predictive value for progression of latent TB infection (LTBI) to active TB than that of the tuberculin skin test (TST) and interferon-gamma release assays (IGRA) is ongoing. In the last decade, evidence for the efficacy and safety of shorter LTBI treatment regimens (i.e. 12 weeks of weekly rifapentine and isoniazid; 4 months of rifampicin; and 4 weeks of daily rifapentine and isoniazid, the latter in human immunodeficiency virus (HIV)-infected persons) as alternatives to 6–9 months of isoniazid has emerged.16-18 The only licensed TB vaccine, BCG (bacille Calmette–Guerin), has been in use since 1920 and does not confer substantial protection against pulmonary TB in adults. Progress in TB vaccine development has been hampered by limited understanding of the protective immune response, lack of immune correlates for protection and the uncertain predictive value of preclinical animal models. There are currently 14 vaccine candidates in clinical trials. Recently, a phase 2b trial of the M72/AS01E vaccine in Africa showed vaccine efficacy of 50% at 3 years for MTB-infected, HIV-negative adults against active pulmonary TB, representing a major breakthrough.19 TB control programmes and health services need to be strengthened to realize the potential of these recent scientific advances. Political leadership and accountability, sustainable funding and investment in research and development, and, not least, addressing the societal and poverty-related drivers of the TB epidemic will be vital in order to achieve WHO's ambitious goal to ‘End TB by 2030’. D.S.C.H. has attended Roche advisory board meetings related to the discussion of baloxavir data and research, but there was no remuneration involved. C.B.E.C. has no conflict of interest.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
张大仙完成签到 ,获得积分10
2秒前
2秒前
秋风的应助被辛勤的唯雪采纳,获得10
2秒前
lx的应助被辛勤的唯雪采纳,获得10
3秒前
3秒前
3秒前
秋风的应助被辛勤的唯雪采纳,获得10
3秒前
lx的应助被辛勤的唯雪采纳,获得10
3秒前
平常迎天的应助被李麟采纳,获得100
3秒前
3秒前
lx的应助被辛勤的唯雪采纳,获得10
3秒前
3秒前
lx的应助被辛勤的唯雪采纳,获得10
3秒前
小白完成签到,获得积分10
4秒前
Pz迷惑的应助被辛勤的唯雪采纳,获得10
4秒前
丁驰发布了新的文献求助10
9秒前
taoliu发布了新的文献求助10
9秒前
null的应助被难得糊涂采纳,获得10
10秒前
12秒前
13秒前
科研通AI2S的应助被YI采纳,获得10
13秒前
14秒前
15秒前
xu完成签到,获得积分10
15秒前
得鹿梦鱼完成签到,获得积分10
15秒前
昏睡的冰枫完成签到 ,获得积分10
16秒前
张天发布了新的文献求助10
18秒前
sunset发布了新的文献求助10
18秒前
19秒前
星光完成签到,获得积分10
20秒前
专注的荣轩完成签到,获得积分10
20秒前
ZD发布了新的文献求助10
21秒前
和信完成签到 ,获得积分10
22秒前
23秒前
阿辉完成签到,获得积分10
24秒前
Monster完成签到,获得积分10
24秒前
绿野仙踪完成签到 ,获得积分10
25秒前
111完成签到,获得积分20
26秒前
26秒前
haoduoyu完成签到 ,获得积分10
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191140
求助须知:如何正确求助?哪些是违规求助? 9578110
关于积分的说明 21856695
捐赠科研通 7790440
什么是DOI,文献DOI怎么找? 3436520
关于科研通互助平台的介绍 2560328
邀请新用户注册赠送积分活动 2483288